These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11369016)

  • 21. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.
    Malave H; Castro M; Burkle J; Voros S; Dayspring T; Honigberg R; Pourfarzib R
    Am J Cardiol; 2012 Sep; 110(5):662-5. PubMed ID: 22621796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
    J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
    Hirano T; Naito H; Kurokawa M; Ebara T; Nagano S; Adachi M; Yoshino G
    Atherosclerosis; 1996 Jun; 123(1-2):57-72. PubMed ID: 8782837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
    Geiss HC; Dietlein M; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):322-4. PubMed ID: 14520596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia.
    Maruyama C; Imamura K; Teramoto T
    J Atheroscler Thromb; 2003; 10(3):186-91. PubMed ID: 14564088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size.
    Krayenbuehl PA; Wiesli P; Schmid C; Lehmann R; Spinas GA; Berneis K
    Swiss Med Wkly; 2008 May; 138(19-20):275-80. PubMed ID: 18491240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a).
    Superko HR; Krauss RM
    J Am Coll Cardiol; 2000 Feb; 35(2):321-6. PubMed ID: 10676676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Lefrandt JD
    Clin Biochem; 2014 Nov; 47(16-17):170-5. PubMed ID: 25149194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
    Tani S; Matsumoto M; Nagao K; Hirayama A
    J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth.
    Burns SF; Lee SJ; Arslanian SA
    J Pediatr; 2012 Dec; 161(6):991-6. PubMed ID: 22809659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.
    Chait A; Brazg RL; Tribble DL; Krauss RM
    Am J Med; 1993 Apr; 94(4):350-6. PubMed ID: 8475928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes.
    Rizzo M; Berneis K; Altinova AE; Toruner FB; Akturk M; Ayvaz G; Rini GB; Spinas GA; Arslan M
    Diabet Med; 2008 Dec; 25(12):1406-11. PubMed ID: 19046238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.
    Matikainen N; Taskinen MR
    Diabet Med; 2013 Jun; 30(6):756-7. PubMed ID: 23215876
    [No Abstract]   [Full Text] [Related]  

  • 40. What is the best predictor of the atherogenic LDL subclass phenotype 'pattern B' in patients with type 2 diabetes mellitus?
    King RI; Florkowski CM; Yeo J; Walmsley TA; Shand BI; Scott RS; George PM
    Ann Clin Biochem; 2011 Mar; 48(Pt 2):166-9. PubMed ID: 21278248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.